My basis was a net reduction in uGAGS
It would need to be significant
Luckily our Brazil P2 was blinded against Placebo, that’s well, rare for a rare clinical program!
It is also broken down by age stratum, unsure we will get the granular view in this read out but potential partners might and agency will! (If data holds up)
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-198
-
- There are more pages in this discussion • 39 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.5¢ |
Change
-0.005(2.38%) |
Mkt cap ! $71.73M | |||
| Open | High | Low | Value | Volume |
| 21.0¢ | 21.0¢ | 19.5¢ | $323.1K | 1.612M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 324 | 20.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.0¢ | 52928 | 5 |
View Market Depth
| Last trade - 16.10pm 28/10/2024 (20 minute delay) ? |
| PAR (ASX) Chart |